KingMylab has supported over 500 clinical projects related to solid tumor research. Our depth of experience and quality of service, as well as our long-term collaborations with leading national and multi-national pharmaceuticals, has helped bring to market many novel Class I therapies in China. We aim to constantly improve our central laboratory capabilities to accelerate the development of innovative drugs in the ongoing fight against cancer.
Services: Drug Concentration, Absorption, Distribution, Metabolism, Excretion, etc.
Platforms: Mass Spectrometry, LAB,etc.
Samples: Blood, Urine, etc.
Services: Anti-drug Antibody, Neutralizing Antibody, etc
Platforms: LBA, CBA, etc
Samples: Blood, etc
Services: PD Markers, etc
Platforms: LBA, NGS, Flow, PCR, Elispot, IHC, etc
Samples: Blood, Urine, Cerebrospinal Fluid, Thoracoabdominal Fluid, Tissue, etc
Services: Safety Markers, etc
Platforms: LBA, Flow, etc
Samples: Blood, Urine, Cerebrospinal Fluid, Thoracoabdominal Fluid, etc
Services: Clinical Endpoint Markers, Exploratory Biomarkers, Tumor Microenvironment, etc
Platforms: IHC, FISH, PCR, NGS, mIHC, Flow, LBA, Olink, etc
Samples: Blood, Urine, Cerebrospinal Fluid, Thoracoabdominal Fluid, Tissue, etc
Services: Marker Confirmation and Detection, etc
Platforms: IHC, PCR, etc
Samples: Tissue, etc